To participate, please register to Mikael Nilimaa on mikael.nilimaa@zoomvision.se or by telephone +46 702 699 322. Internet broadcast:
A live broadcast from the presentation will be available on Internet, February 10 at 3 p.m. (CET): www.biovitrum.com.
Telephone conference call: You may also participate with questions by telephone.
Dial-in numbers: S: +46 8 505 598 53 UK: 44 20 304 324 36 US : +1 866 458 40 87
The presentation material will be published on our web site after the meeting together with the archived web cast, please go to: www.biovitrum.com.
About Biovitrum
Biovitrum is a Swedish pharmaceutical company. The company markets a range of specialist pharmaceuticals internationally. Using its expertise and experience Biovitrum takes scientific innovation all the way to the market and to specialist indication patients with significant medical need. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within our prioritized areas of hemophilia, inflammation/autoimmune diseases and malabsorption. The company has revenues of approximately SEK 1.3 billion and around 500 employees. It is listed on the OMX Nordic Exchange in Stockholm. For more information go to www.biovitrum.com.